ArticleNAR cancer2021
Characterization of a
Open access · goldAbstract read
In one paragraph
Article in NAR cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.JCO precision oncology · 2023Trial
- BCLXSignal transduction and targeted therapy · 2026Article
- Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.Science translational medicine · 2026Article
- CTPS1 is an unexplored vulnerability in breast and ovarian cancer.Theranostics · 2026Article
- Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance.Nucleic acids research · 2025Article
- Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer.NPJ precision oncology · 2025Article
- Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines.Cancer research communications · 2024Article
- Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.International journal of molecular sciences · 2024Article
- High-level tumour methylation ofNAR cancer · 2024Article
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- The role of aberrant DNA methylation in cancer initiation and clinical impacts.Therapeutic advances in medical oncology · 2024Article
- BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges.Frontiers in oncology · 2024Review
- Clinical and translational advances in ovarian cancer therapy.Nature cancer · 2023Review
- The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Nature communications · 2023Article
- epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data.GigaScience · 2022Article
- Resistance to DNA repair inhibitors in cancer.Molecular oncology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 6 institutions in 3 countries.
Rachel M HurleyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Cordelia D McGeheeDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Ksenija NesicThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Cristina CorreiaDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Taylor M WeiskittelDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Rebecca L KellyDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Annapoorna VenkatachalamDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Xiaonan HouDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Nicholas M PathoulasDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
X Wei MengDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Olga KondrashovaThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Marc R RadkeDepartment of Obstetrics & Gynecology, University of Washington, Seattle, WA 98195, USA.
Paula A SchneiderDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Karen S FlattenDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Kevin L PetersonDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905 USA.
Marc A BeckerDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Ee Ming WongPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria 3800, Australia.
Melissa S SoutheyPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria 3800, Australia.
Alexander DobrovicUniversity of Melbourne Department of Surgery, Austin Hospital, Heidelberg, Victoria 3084, Australia.ORCID https://orcid.org/0000-0003-3414-112X
Kevin K LinClovis Oncology, San Francisco, CA 94158, USA.
Thomas C HardingClovis Oncology, San Francisco, CA 94158, USA.
Iain McNeishDivision of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, W12 0NN United Kingdom.
Christian A RossDivision of Information Technology, Mayo Clinic, Rochester, MN 55905, USA.
Jill M WagnerDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Matthew J WakefieldThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Clare L ScottThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Paul HaluskaDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Andrea E Wahner HendricksonDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Larry M KarnitzDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
Elizabeth M SwisherDepartment of Obstetrics & Gynecology, University of Washington, Seattle, WA 98195, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.
S John WerohaDivision of Medical Oncology, Mayo Clinic, Rochester, MN 55905 USA.
Scott H KaufmannDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905 USA.ORCID https://orcid.org/0000-0002-4900-7145
Mayo Clinic · USThe University of Melbourne · AUClovis Oncology (United States) · USUniversity of Washington · USHammersmith Hospital · GBMayo Clinic in Arizona · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI SCOTT H KAUFMANN · 2009 to 2026
$37.0MPredoctoral Training Program in Molecular PharmacologyT32GM072474 · NIGMS · MAYO CLINIC ROCHESTER · PI KARNITZ, LARRY M · 2005 to 2020
$2.4MA Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian CancerF30CA213737 · NCI · MAYO CLINIC ROCHESTER · PI MCGEHEE, CORDELIA · 2017 to 2021
$190kNCI NIH HHS F30 CA213737NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NIGMS NIH HHS T32 GM072474
Abstract
Acquired PARP inhibitor (PARPi) resistance in
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.